Theranos has been on quite the roller-coaster ride lately — and it hasn’t been pretty. But it looks like the next attempt at reputation and credibility redemption comes in the form of an expanded Medical Advisory Board.
The company recently hosted three scientific review sessions in Palo Alto with leading laboratory and medical experts who were invited to review the company’s proprietary technologies.
The 5 Best Software to Buy for Managing a Spa Franchise
Choosing the right software translates directly into better client management, operational efficiency and growth for your spa franchise. Discover which tool is best for your business.
According to an email from a spokesperson, those in attendance had full exposure to all current systems, devices and data. If that’s the case, they are jumping in head-first to what has publicly appeared to be a faulty operation and are willing to potentially pull the company back up.
Theranos’ Scientific & Medical Advisory Board members now include:
- Susan A. Evans, PhD, FACB, former president of the American Association For Clinical Chemistry (AACC)
- Bill Foege, MD, former Director of the U.S. Center for Disease Control and Prevention (CDC)
- Ann M. Gronowski, PhD, DABCC, Department of Pathology and Immunology and the Department of Obstetrics and Gynecology at the Washington University School of Medicine in St. Louis
- David Helfet, MD, Hospital for Special Surgery and New York-Presbyterian Hospital, Weill Cornell Medicine
- Larry J. Kricka, D. Phil, FRCPath, University of Pennsylvania
- Jack Ladenson, PhD, DABCC, Washington University School of Medicine;
- Andy O. Miller, MD, Hospital for Special Surgery and New York-Presbyterian Hospital, Weill Cornell Medicine
- Steven Spitalnik, MD, Columbia University Medical Center (CUMC)
Out of the eight members announced as part of the new board, only two are those who were previously involved – Dr. Foege and Dr. Helfet.
Understanding EGPA: The Role of Eosinophils and Advancements in Treatment Options
FASENRA® (benralizumab) injection, for subcutaneous use, 30 mg is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). FASENRA provides a treatment option for HCPs to consider when managing this challenging disease.
Maybe this new board indicates that Theranos could make a comeback from the significant criticism in recent months.
Photo: Flickr user Steve Jurvetson